Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma.

Troppan K, Deutsch A, Gerger A, Stojakovic T, Beham-Schmid C, Wenzl K, Neumeister P, Pichler M.

Br J Cancer. 2014 Jan 21;110(2):369-74. doi: 10.1038/bjc.2013.763. Epub 2013 Dec 19.

PMID:
24357794
[PubMed - indexed for MEDLINE]
2.

External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.

Szkandera J, Stotz M, Eisner F, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Ress AL, Seggewies FS, Gerger A, Hoefler G, Pichler M.

PLoS One. 2013 Nov 4;8(11):e78225. doi: 10.1371/journal.pone.0078225. eCollection 2013.

PMID:
24223776
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.

Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M.

Br J Cancer. 2014 Jul 8;111(1):55-60. doi: 10.1038/bjc.2014.277. Epub 2014 May 29.

PMID:
24874478
[PubMed - indexed for MEDLINE]
4.

A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients.

Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A.

Br J Cancer. 2013 Jul 23;109(2):395-400. doi: 10.1038/bjc.2013.346. Epub 2013 Jul 2.

PMID:
23820252
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma.

Dalpiaz O, Pichler M, Mannweiler S, Martín Hernández JM, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC.

Br J Cancer. 2014 May 13;110(10):2531-6. doi: 10.1038/bjc.2014.180. Epub 2014 Apr 1.

PMID:
24691424
[PubMed - indexed for MEDLINE]
6.

Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.

Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.

J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.

PMID:
22099932
[PubMed - indexed for MEDLINE]
Free Article
7.

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.

Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M.

Br J Cancer. 2013 Jul 23;109(2):416-21. doi: 10.1038/bjc.2013.332. Epub 2013 Jun 25. Erratum in: Br J Cancer. 2013 Oct 1;109(7):2026. Zoughbi, W [corrected to AlZoughbi, W].

PMID:
23799847
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.

Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R.

Br J Cancer. 2013 Mar 5;108(4):901-7. doi: 10.1038/bjc.2013.28. Epub 2013 Feb 5.

PMID:
23385728
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio.

Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN.

Am J Hematol. 2010 Nov;85(11):896-9. doi: 10.1002/ajh.21849.

PMID:
20842639
[PubMed - indexed for MEDLINE]
10.

Primary gastric non-Hodgkin's lymphoma: clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma.

Ibrahim EM, Ezzat AA, Raja MA, Rahal MM, Ajarim DS, Mann B, Baloush A, Stuart RK, Bazarbashi SN.

Ann Oncol. 1999 Dec;10(12):1441-9.

PMID:
10643534
[PubMed - indexed for MEDLINE]
Free Article
11.

Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.

Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.

Eur J Haematol. 2008 Dec;81(6):448-53. doi: 10.1111/j.1600-0609.2008.01129.x. Epub 2008 Aug 6.

PMID:
18691256
[PubMed - indexed for MEDLINE]
12.

Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?

Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, Somali I, Demir L, Bayoglu IV, Yildiz Y, Akyol M, Koyuncu B, Coban E, Ulger E, Unay FC, Tarhan MO.

Int J Clin Oncol. 2014 Feb 18. [Epub ahead of print]

PMID:
24532163
[PubMed - as supplied by publisher]
13.

Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.

Chae YS, Shin H, Sohn SK, Lee SJ, Moon JH, Kang BW, Kim JG, Yang DH, Lee JJ, Park TI.

Leuk Lymphoma. 2012 Sep;53(9):1757-63. doi: 10.3109/10428194.2012.670231. Epub 2012 Apr 19.

PMID:
22372848
[PubMed - indexed for MEDLINE]
14.

[Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].

Fu ZY, Zhu J, Song YQ, Liu WP, Ji XQ, Zhan SY.

Beijing Da Xue Xue Bao. 2014 Jun 18;46(3):405-11. Chinese.

PMID:
24943019
[PubMed - in process]
Free Article
15.

Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.

Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST.

Ann Hematol. 2009 May;88(5):417-24. doi: 10.1007/s00277-008-0604-7. Epub 2008 Sep 7.

PMID:
18777110
[PubMed - indexed for MEDLINE]
16.

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.

Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, Aloe-Spiriti MA.

Leuk Lymphoma. 2008 Sep;49(9):1745-51. doi: 10.1080/10428190802226425.

PMID:
18798109
[PubMed - indexed for MEDLINE]
17.

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.

Yhim HY, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, Kim JS, Choi CW, Oh SY, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Lee JJ, Sung HJ, Kim HJ, Lee DH, Suh C, Kwak JY.

BMC Cancer. 2010 Jun 22;10:321. doi: 10.1186/1471-2407-10-321.

PMID:
20569446
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?

Laskar S, Bahl G, Muckaden MA, Nair R, Gupta S, Bakshi A, Gujral S, Shet T, Shrivastava SK, Dinshaw KA.

Cancer. 2007 Aug 15;110(4):816-23.

PMID:
17582622
[PubMed - indexed for MEDLINE]
Free Article
19.

Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.

Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ.

PLoS One. 2012;7(7):e41658. doi: 10.1371/journal.pone.0041658. Epub 2012 Jul 23.

PMID:
22911837
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.

Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH, Yu YB.

Ann Hematol. 2013 Nov;92(11):1513-20. doi: 10.1007/s00277-013-1807-0. Epub 2013 Jun 18.

PMID:
23775580
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk